Browsing by Author "Baumbach, Andreas (56962775900)"
Now showing 1 - 7 of 7
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up(2022) ;Baigent, Colin (57224792507) ;Windecker, Stephan (7003473419) ;Andreini, Daniele (8342392800) ;Arbelo, Elena (16066822500) ;Barbato, Emanuele (58118036500) ;Bartorelli, Antonio L. (7005844246) ;Baumbach, Andreas (56962775900) ;Behr, Elijah R. (6701515513) ;Berti, Sergio (7005673335) ;Bueno, Héctor (57218323754) ;Capodanno, Davide (25642544700) ;Cappato, Riccardo (7006770623) ;Chieffo, Alaide (57202041611) ;Collet, Jean-Philippe (7102328222) ;Cuisset, Thomas (14627332500) ;De Simone, Giovanni (55515626600) ;Delgado, Victoria (24172709900) ;Dendale, Paul (7003942842) ;Dudek, Dariusz (7006649800) ;Edvardsen, Thor (6603263370) ;Elvan, Arif (6602334375) ;González-Juanatey, José R. (7005529659) ;Gori, Mauro (9044805200) ;Grobbee, Diederick (7103100613) ;Guzik, Tomasz J. (7003467849) ;Halvorsen, Sigrun (9039942100) ;Haude, Michael (7006762859) ;Heidbuchel, Hein (7004984289) ;Hindricks, Gerhard (35431335000) ;Ibanez, Borja (13907649300) ;Karam, Nicole (25027722300) ;Katus, Hugo (24299225600) ;Klok, Fredrikus A. (16301310900) ;Konstantinides, Stavros V. (7003963321) ;Landmesser, Ulf (6602879397) ;Leclercq, Christophe (59630023200) ;Leonardi, Sergio (36059439800) ;Lettino, Maddalena (6602951700) ;Marenzi, Giancarlo (7004643683) ;Mauri, Josepa (35453670900) ;Metra, Marco (7006770735) ;Morici, Nuccia (14016177400) ;Mueller, Christian (57638261900) ;Petronio, Anna Sonia (56604816300) ;Polovina, Marija M. (35273422300) ;Potpara, Tatjana (57216792589) ;Praz, Fabien (23009701400) ;Prendergast, Bernard (20135595700) ;Prescott, Eva (15036718700) ;Price, Susanna (7202475463) ;Pruszczyk, Piotr (7003926604) ;Rodríguez-Leor, Oriol (8045469300) ;Roffi, Marco (7004532440) ;Romaguera, Rafael (24345130100) ;Rosenkranz, Stephan (55190823300) ;Sarkozy, Andrea (8867294000) ;Scherrenberg, Martijn (57204193502) ;Seferovic, Petar (6603594879) ;Senni, Michele (7003359867) ;Spera, Francesco R. (56583947800) ;Stefanini, Giulio (14050996500) ;Thiele, Holger (57223640812) ;Tomasoni, Daniela (57214231971) ;Torracca, Lucia (6603743705) ;Touyz, Rhian M. (7005833567) ;Wilde, Arthur A. (7102614930)Williams, Bryan (57198065489)Aims: Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular (CV) disease in association with COVID-19. Methods and results: A narrative literature review of the available evidence has been performed, and the resulting information has been organized into two parts. The first, which was reported previously, focused on the epidemiology, pathophysiology, and diagnosis of CV conditions that may be manifest in patients with COVID-19. This second part addresses the topics of: care pathways and triage systems and management and treatment pathways, both of the most commonly encountered CV conditions and of COVID-19; and information that may be considered useful to help patients with CV disease (CVD) to avoid exposure to COVID-19. Conclusion: This comprehensive review is not a formal guideline but rather a document that provides a summary of current knowledge and guidance to practicing clinicians managing patients with CVD and COVID-19. The recommendations are mainly the result of observations and personal experience from healthcare providers. Therefore, the information provided here may be subject to change with increasing knowledge, evidence from prospective studies, and changes in the pandemic. Likewise, the guidance provided in the document should not interfere with recommendations provided by local and national healthcare authorities. © The European Society of Cardiology 2021. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: Part 2-care pathways, treatment, and follow-up(2022) ;Baigent, Colin (57224792507) ;Windecker, Stephan (7003473419) ;Andreini, Daniele (8342392800) ;Arbelo, Elena (16066822500) ;Barbato, Emanuele (57848364200) ;Bartorelli, Antonio L. (7005844246) ;Baumbach, Andreas (56962775900) ;Behr, Elijah R. (6701515513) ;Berti, Sergio (57201104586) ;Bueno, Héctor (57218323754) ;Capodanno, Davide (25642544700) ;Cappato, Riccardo (7006770623) ;Chieffo, Alaide (57202041611) ;Collet, Jean-Philippe (7102328222) ;Cuisset, Thomas (14627332500) ;De Simone, Giovanni (55515626600) ;Delgado, Victoria (24172709900) ;Dendale, Paul (7003942842) ;Dudek, Dariusz (7006649800) ;Edvardsen, Thor (6603263370) ;Elvan, Arif (6602334375) ;González-Juanatey, José R. (57226232704) ;Gori, Mauro (9044805200) ;Grobbee, Diederick (57216110328) ;Guzik, Tomasz J. (7003467849) ;Halvorsen, Sigrun (9039942100) ;Haude, Michael (7006762859) ;Heidbuchel, Hein (7004984289) ;Hindricks, Gerhard (35431335000) ;Ibanez, Borja (13907649300) ;Karam, Nicole (25027722300) ;Katus, Hugo (57193159685) ;Klok, Fredrikus A. (16301310900) ;Konstantinides, Stavros V. (7003963321) ;Landmesser, Ulf (6602879397) ;Leclercq, Christophe (59630023200) ;Leonardi, Sergio (36059439800) ;Lettino, Maddalena (6602951700) ;Marenzi, Giancarlo (7004643683) ;Mauri, Josepa (35453670900) ;Metra, Marco (7006770735) ;Morici, Nuccia (14016177400) ;Mueller, Christian (57638261900) ;Petronio, Anna Sonia (56604816300) ;Polovina, Marija M. (35273422300) ;Potpara, Tatjana (57216792589) ;Praz, Fabien (23009701400) ;Prendergast, Bernard (20135595700) ;Prescott, Eva (15036718700) ;Price, Susanna (7202475463) ;Pruszczyk, Piotr (7003926604) ;Rodríguez-Leor, Oriol (8045469300) ;Roffi, Marco (7004532440) ;Romaguera, Rafael (24345130100) ;Rosenkranz, Stephan (55190823300) ;Sarkozy, Andrea (8867294000) ;Seferovic, Petar (55873742100) ;Senni, Michele (7003359867) ;Spera, Francesco R. (56583947800) ;Stefanini, Giulio (14050996500) ;Thiele, Holger (57223640812) ;Tomasoni, Daniela (57214231971) ;Torracca, Lucia (6603743705) ;Touyz, Rhian M. (7005833567) ;Wilde, Arthur A. (57224960950)Williams, Bryan (57198065489)Aims: Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular (CV) disease in association with COVID-19. Methods and results: A narrative literature review of the available evidence has been performed, and the resulting information has been organized into two parts. The first, which was reported previously, focused on the epidemiology, pathophysiology, and diagnosis of CV conditions that may be manifest in patients with COVID-19. This second part addresses the topics of: care pathways and triage systems and management and treatment pathways, both of the most commonly encountered CV conditions and of COVID-19; and information that may be considered useful to help patients with CV disease (CVD) to avoid exposure to COVID-19. Conclusion: This comprehensive review is not a formal guideline but rather a document that provides a summary of current knowledge and guidance to practicing clinicians managing patients with CVD and COVID-19. The recommendations are mainly the result of observations and personal experience from healthcare providers. Therefore, the information provided here may be subject to change with increasing knowledge, evidence from prospective studies, and changes in the pandemic. Likewise, the guidance provided in the document should not interfere with recommendations provided by local and national healthcare authorities. © 2021 The European Society of Cardiology. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1 - epidemiology, pathophysiology, and diagnosis(2022) ;Baigent, Colin (57224792507) ;Windecker, Stephan (7003473419) ;Andreini, Daniele (8342392800) ;Arbelo, Elena (16066822500) ;Barbato, Emanuele (58118036500) ;Bartorelli, Antonio L. (7005844246) ;Baumbach, Andreas (56962775900) ;Behr, Elijah R. (6701515513) ;Berti, Sergio (7005673335) ;Bueno, Héctor (57218323754) ;Capodanno, Davide (25642544700) ;Cappato, Riccardo (7006770623) ;Chieffo, Alaide (57202041611) ;Collet, Jean-Philippe (7102328222) ;Cuisset, Thomas (14627332500) ;De Simone, Giovanni (55515626600) ;Delgado, Victoria (24172709900) ;Dendale, Paul (7003942842) ;Dudek, Dariusz (7006649800) ;Edvardsen, Thor (6603263370) ;Elvan, Arif (6602334375) ;González-Juanatey, José R. (7005529659) ;Gori, Mauro (9044805200) ;Grobbee, Diederick (7103100613) ;Guzik, Tomasz J. (7003467849) ;Halvorsen, Sigrun (9039942100) ;Haude, Michael (7006762859) ;Heidbuchel, Hein (7004984289) ;Hindricks, Gerhard (35431335000) ;Ibanez, Borja (13907649300) ;Karam, Nicole (25027722300) ;Katus, Hugo (24299225600) ;Klok, Fredrikus A. (16301310900) ;Konstantinides, Stavros V. (7003963321) ;Landmesser, Ulf (6602879397) ;Leclercq, Christophe (59630023200) ;Leonardi, Sergio (36059439800) ;Lettino, Maddalena (6602951700) ;Marenzi, Giancarlo (7004643683) ;Mauri, Josepa (35453670900) ;Metra, Marco (7006770735) ;Morici, Nuccia (14016177400) ;Mueller, Christian (57638261900) ;Petronio, Anna Sonia (56604816300) ;Polovina, Marija M. (35273422300) ;Potpara, Tatjana (57216792589) ;Praz, Fabien (23009701400) ;Prendergast, Bernard (20135595700) ;Prescott, Eva (15036718700) ;Price, Susanna (7202475463) ;Pruszczyk, Piotr (7003926604) ;Rodríguez-Leor, Oriol (8045469300) ;Roffi, Marco (7004532440) ;Romaguera, Rafael (24345130100) ;Rosenkranz, Stephan (55190823300) ;Sarkozy, Andrea (8867294000) ;Scherrenberg, Martijn (57204193502) ;Seferovic, Petar (6603594879) ;Senni, Michele (7003359867) ;Spera, Francesco R. (56583947800) ;Stefanini, Giulio (14050996500) ;Thiele, Holger (57223640812) ;Tomasoni, Daniela (57214231971) ;Torracca, Lucia (6603743705) ;Touyz, Rhian M. (7005833567) ;Wilde, Arthur A. (7102614930)Williams, Bryan (57198065489)Aims: Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two-part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular disease (CVD) in association with COVID-19. Methods and results: A narrative literature review of the available evidence has been performed, and the resulting information has been organized into two parts. The first, reported here, focuses on the epidemiology, pathophysiology, and diagnosis of cardiovascular (CV) conditions that may be manifest in patients with COVID-19. The second part, which will follow in a later edition of the journal, addresses the topics of care pathways, treatment, and follow-up of CV conditions in patients with COVID-19. Conclusion: This comprehensive review is not a formal guideline but rather a document that provides a summary of current knowledge and guidance to practicing clinicians managing patients with CVD and COVID-19. The recommendations are mainly the result of observations and personal experience from healthcare providers. Therefore, the information provided here may be subject to change with increasing knowledge, evidence from prospective studies, and changes in the pandemic. Likewise, the guidance provided in the document should not interfere with recommendations provided by local and national healthcare authorities. © 2021 The European Society of Cardiology. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis(2022) ;Baigent, Colin (57224792507) ;Windecker, Stephan (7003473419) ;Andreini, Daniele (8342392800) ;Arbelo, Elena (16066822500) ;Barbato, Emanuele (58118036500) ;Bartorelli, Antonio L. (7005844246) ;Baumbach, Andreas (56962775900) ;Behr, Elijah R. (6701515513) ;Berti, Sergio (7005673335) ;Bueno, Héctor (57218323754) ;Capodanno, Davide (25642544700) ;Cappato, Riccardo (7006770623) ;Chieffo, Alaide (57202041611) ;Collet, Jean-Philippe (7102328222) ;Cuisset, Thomas (14627332500) ;De Simone, Giovanni (55515626600) ;Delgado, Victoria (24172709900) ;Dendale, Paul (7003942842) ;Dudek, Dariusz (7006649800) ;Edvardsen, Thor (6603263370) ;Elvan, Arif (6602334375) ;González-Juanatey, José R. (7005529659) ;Gori, Mauro (9044805200) ;Grobbee, Diederick (7103100613) ;Guzik, Tomasz J. (7003467849) ;Halvorsen, Sigrun (9039942100) ;Haude, Michael (7006762859) ;Heidbuchel, Hein (7004984289) ;Hindricks, Gerhard (35431335000) ;Ibanez, Borja (13907649300) ;Karam, Nicole (25027722300) ;Katus, Hugo (24299225600) ;Klok, Fredrikus A. (16301310900) ;Konstantinides, Stavros V. (7003963321) ;Landmesser, Ulf (6602879397) ;Leclercq, Christophe (59630023200) ;Leonardi, Sergio (36059439800) ;Lettino, Maddalena (6602951700) ;Marenzi, Giancarlo (7004643683) ;Mauri, Josepa (35453670900) ;Metra, Marco (7006770735) ;Morici, Nuccia (14016177400) ;Mueller, Christian (57638261900) ;Petronio, Anna Sonia (56604816300) ;Polovina, Marija M. (35273422300) ;Potpara, Tatjana (57216792589) ;Praz, Fabien (23009701400) ;Prendergast, Bernard (20135595700) ;Prescott, Eva (15036718700) ;Price, Susanna (7202475463) ;Pruszczyk, Piotr (7003926604) ;Rodríguez-Leor, Oriol (8045469300) ;Roffi, Marco (7004532440) ;Romaguera, Rafael (24345130100) ;Rosenkranz, Stephan (55190823300) ;Sarkozy, Andrea (8867294000) ;Scherrenberg, Martijn (57204193502) ;Seferovic, Petar (6603594879) ;Senni, Michele (7003359867) ;Spera, Francesco R. (56583947800) ;Stefanini, Giulio (14050996500) ;Thiele, Holger (57223640812) ;Tomasoni, Daniela (57214231971) ;Torracca, Lucia (6603743705) ;Touyz, Rhian M. (7005833567) ;Wilde, Arthur A. (7102614930)Williams, Bryan (57198065489)Aims:Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two-part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular disease (CVD) in association with COVID-19. Methods and results: A narrative literature review of the available evidence has been performed, and the resulting information has been organized into two parts. The first, reported here, focuses on the epidemiology, pathophysiology, and diagnosis of cardiovascular (CV) conditions that may be manifest in patients with COVID-19. The second part, which will follow in a later edition of the journal, addresses the topics of care pathways, treatment, and follow-up of CV conditions in patients with COVID-19. Conclusion: This comprehensive review is not a formal guideline but rather a document that provides a summary of current knowledge and guidance to practicing clinicians managing patients with CVD and COVID-19. The recommendations are mainly the result of observations and personal experience from healthcare providers. Therefore, the information provided here may be subject to change with increasing knowledge, evidence from prospective studies, and changes in the pandemic. Likewise, the guidance provided in the document should not interfere with recommendations provided by local and national healthcare authorities. © The European Society of Cardiology 2021. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication Selective use of contemporary drug-eluting stents in primary angioplasty for ST-elevation myocardial infarction: Pooled analysis of COMFORTABLE AMI and EXAMINATION(2017) ;Baumbach, Andreas (56962775900) ;Heg, Dik (6701630557) ;Räber, Lorenz (8670514700) ;Ostoijc, Miodrag (55210899800) ;Brugaletta, Salvatore (14010425300) ;Strange, Julian W. (7006073350) ;Johnson, Thomas W. (56418917800) ;Jüni, Peter (7004263326) ;Engstrøm, Thomas (7004069840) ;Serruys, Patrick W. (34573036500) ;Sabaté, Manel (57193753144)Windecker, Stephan (7003473419)Aims: Selective use of DES only in patients at higher risk of MACE is common practice, particularly in healthcare systems with a large premium payable for DES. We aimed to identify subgroups of patients in which the use of BMS in primary percutaneous coronary intervention (PPCI) for STEMI can still be justified. Methods and results: We performed a patient-level pooled analysis of COMFORTABLE AMI and EXAMINATION comparing contemporary DES with BMS in PPCI. A risk score was applied using three parameters: lesion length >15mm, vessel size <3 mm, and diabetes mellitus. Individual data were available for 2,655 patients. The incidence of MACE at one year was incrementally higher in patients with risk scores of 1 or 2/3. MACE rates were lower in patients with a risk score 0 or 1 who were treated with DES (p=0.0073 and p=0.008). No difference in death or reinfarction was seen between DES and BMS in any group. There was a significant reduction in TLR with DES in all three groups. Conclusions: A score comprising vessel size, lesion length, and diabetes did not identify patients at low risk with equivalent or better results from BMS use. The results suggest that the practice of only selective use of DES in primary PCI should be discouraged. © Europa Digital & Publishing 2017. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication Stepwise provisional versus systematic culotte for stenting of true coronary bifurcation lesions: five-year follow-up of the multicentre randomised EBC TWO Trial(2023) ;Arunothayaraj, Sandeep (36140221200) ;Behan, Miles W. (8862299400) ;Lefèvre, Thierry (13608617100) ;Lassen, Jens F. (57189389659) ;Chieffo, Alaide (57202041611) ;Stankovic, Goran (59150945500) ;Burzotta, Francesco (7003405739) ;Pan, Manuel (7202544866) ;Ferenc, Miroslaw (8933716300) ;Hovasse, Thomas (25627893900) ;Spence, Mark S. (7103007124) ;Brunel, Philippe (7006007671) ;Cotton, James M. (7102218822) ;Cockburn, James (43661048500) ;Carrié, Didier (7006798967) ;Baumbach, Andreas (56962775900) ;Maeng, Michael (20034699800) ;Louvard, Yves (7004523655)Hildick-Smith, David (8089365300)Background: The multicentre European Bifurcation Club Trial (EBC TWO) showed no significant differences in 12-month clinical outcomes between patients randomised to a provisional stenting strategy or systematic culotte stenting in non-left main true bifurcations. Aims: This study aimed to investigate the 5-year clinical results of the EBC TWO Trial. Methods: A total of 200 patients undergoing stent implantation for non-left main bifurcation lesions were recruited into EBC TWO. Inclusion criteria required a side branch diameter ≥2.5 mm and side branch lesion length >5 mm. Five-year follow-up was completed for 197 patients. The primary endpoint was the composite of all-cause mortality, myocardial infarction, or target vessel revascularisation. Results: The mean side branch stent diameter was 2.7±0.3 mm and mean side branch lesion length was 10.3±7.2 mm. At 5-year follow-up, the primary endpoint occurred in 18.4% of provisional and 23.7% of systematic culotte patients (hazard ratio [HR] 0.75, 95% confidence interval [CI]: 0.41-1.38). No significant differences were identified individually for all-cause mortality (7.8% vs 7.2%, HR 1.11, 95% CI: 0.40-3.05), myocardial infarction (8.7% vs 13.4%, HR 0.64, 95% CI: 0.27-1.50) or target vessel revascularisation (6.8% vs 9.3%, HR 1.12, 95% CI: 0.37-3.34). Stent thrombosis rates were also similar (1.9% vs 3.1%, HR 0.63, 95% CI: 0.11-3.75). There was no significant interaction between the extent of side branch disease and the primary outcome (p=0.34). Conclusions: In large non-left main true bifurcation lesions, the use of a systematic culotte strategy showed no benefit over provisional stenting for the composite outcome of all-cause mortality, myocardial infarction, or target vessel revascularisation at 5 years. The stepwise provisional approach may be considered preferable for the majority of true coronary bifurcation lesions. © Europa Digital & Publishing 2023. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication The EBC TWO Study (European Bifurcation Coronary TWO): A Randomized Comparison of Provisional T-Stenting Versus a Systematic 2 Stent Culotte Strategy in Large Caliber True Bifurcations(2016) ;Hildick-Smith, David (8089365300) ;Behan, Miles W. (8862299400) ;Lassen, Jens F. (57189389659) ;Chieffo, Alaide (57202041611) ;Lefèvre, Thierry (13608617100) ;Stankovic, Goran (59150945500) ;Burzotta, Francesco (7003405739) ;Pan, Manuel (7202544866) ;Ferenc, Miroslaw (8933716300) ;Bennett, Lorraine (35847475900) ;Hovasse, Thomas (25627893900) ;Spence, Mark S. (7103007124) ;Oldroyd, Keith (7003557589) ;Brunel, Philippe (7006007671) ;Carrie, Didier (7006798967) ;Baumbach, Andreas (56962775900) ;Maeng, Michael (20034699800) ;Skipper, Nicola (56108237700)Louvard, Yves (7004523655)Background-For the treatment of coronary bifurcation lesions, a provisional strategy is superior to systematic 2-stent techniques for the most bifurcation lesions. However, complex anatomies with large side branches (SBs) with significant ostial disease length are considered by expert consensus to warrant a 2-stent technique upfront. This consensus view has not been scientifically assessed. Methods and Results-Symptomatic patients with large caliber true bifurcation lesions (SB diameter ≥2.5 mm) and significant ostial disease length (≥5 mm) were randomized to either a provisional T-stent strategy or a dual stent culotte technique. Two hundred patients aged 64±10 years, 82% male, were randomized in 20 European centers. The clinical presentations were stable coronary disease (69%) and acute coronary syndromes (31%). SB stent diameter (2.67±0.27 mm) and length (20.30±5.89 mm) confirmed the extent of SB disease. Procedural success (provisional 97%, culotte 94%) and kissing balloon inflation (provisional 95%, culotte 98%) were high. Sixteen percent of patients in the provisional group underwent T-stenting. The primary end point (a composite of death, myocardial infarction, and target vessel revascularization at 12 months) occurred in 7.7% of the provisional T-stent group versus 10.3% of the culotte group (hazard ratio, 1.02; 95% confidence interval, 0.78-1.34; P=0.53). Procedure time, X-ray dose, and cost all favored the simpler procedure. Conclusions-When treating complex coronary bifurcation lesions with large stenosed SBs, there is no difference between a provisional T-stent strategy and a systematic 2-stent culotte strategy in a composite end point of death, myocardial infarction, and target vessel revascularization at 12 months. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT 01560455. © 2016 American Heart Association, Inc.
